Lifespan extension therapy:  Prostaglandin J2 (PGJ2) may increase life span via up-regulation of its target gene BubR1, 15/January/2018, 4.55 am

Anti-infective Therapy: Fisetin, isolated from A.Greggi and A.Berlanderi among others,  inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 15/January/2018,  4.41 am
January 14, 2018
Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Fluvastatin, Epicatechin and Matrine (ANEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 15/January/2018, 5.07 am
January 14, 2018
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.

What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Lifespan extension therapy:  Prostaglandin D2 (PGD2) may increase life span via up-regulation of its target gene BubR1

What is known? 

Prostaglandin J2 (PGD2) has been shown to protect against high-blood sugar induced pathological conditions. However, the exact mechanism of action is far from clear.

From research findings to therapeutic Opportunity: 

This study suggests, for the first time, that Prostaglandin J2 (PGJ2)by increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

[easy_payment currency=”USD”]

Figure 1. Prostaglandin D2 (PGJ2)  may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

Figure 2. Prostaglandin D2 (PGJ2)  may function as a longevity-promoting agent.


Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing “Prostaglandin J2 (PGJ2) or its analogues, either alone or in combination with other drugsat lower doses may be used to extend the lifespan of an individual (fig. 1).

Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How Prostaglandin J2 (PGJ2)  increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply

# Research cooperation


Web: or

CitationBoominathan, L., Lifespan extension therapy:  Prostaglandin J2 (PGJ2) may increase life span via up-regulation of its target gene BubR1, 15/January/2018, 4.56 am,  Genome-2-Bio-Medicine Discovery center (GBMD),

Courtesy: When you cite drop us a line at

Comments are closed.